Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
386. |
ECCT/21/09/08 | GBT133_Inclacumab Open-Label An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Bernhards Ragama Ogutu 3. Videlis N Nduba 4. Prof Jessie N Githanga Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
View |
387. |
ECCT/22/08/03 | NeoSep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of clinically diagnosed neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Christina Wesonga Obiero 2. James Alexander Berkley Site(s) in Kenya 1. Kilifi County Hospital, KEMRI- Wellcome Trust Research Programme (KWTRP) (Kilifi county) |
View |
388. |
ECCT/17/08/09 | A trial to compare two new combinations of antimalarial drugs with the standard combination of antimalarial drugs in Kenyan children An open-label randomised trial to assess the therapeutic efficacy and tolerability of arterolane-piperaquine plus single low dose primaquine versus arterolane-piperaquine plus mefloquine and single low dose primaquine versus artemether-lumefantrine plus single low dose primaquine in the treatment of uncomplicated falciparum malaria in children in Kenya. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya 1. Kilifi County Hospital - Paediatric Out patient and Inpatient department (Kilifi county) 2. Pingilikani Dispensary (Kilifi county) |
View |
389. |
ECCT/25/01/01 | FLORAL An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Bernhard Ogutu Site(s) in Kenya 1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 2. Gertrude’s Children’s Hospital (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 5. KEMRI WALTER REED KERICHO (Kericho county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) |
View |
390. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
View |